Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026
In this episode, experts discuss the rapidly evolving bladder cancer treatment landscape, including new options for BCG-unresponsive disease, emerging perioperative regimens, and the growing role of biomarkers and multidisciplinary care in guiding treatment decisions.
Decera Clinical Education Oncology Podcast · Sam S. Chang MD MBA, Matthew D. Galsky MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including:
- New treatment options for BCG-unresponsive non–muscle-invasive bladder cancer
- Intravesical therapies such as nadofaragene and N-803
- The role of ctDNA in measurable residual disease detection
Presenters:
Sam S. Chang, MD, MBA
Patricia and Rodes Hart Chair of Urologic Surgery
Chief Surgical Officer
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
Matthew D. Galsky, MD
Lillian and Howard Stratton Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York
Link to full program:
https://bit.ly/479RgQn
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.